GRAL investors face August 4 deadline in Grail securities lawsuit
Investors who bought Grail between May 13, 2025 and Feb 19, 2026 must file by Aug 4, 2026 to join a fraud action after a 50% drop.Summary
Grail, a commercial‑stage company focused on early cancer detection, saw its shares plunge 50.55% after the company announced that the NHS‑Galleri trial failed to meet its primary endpoint, wiping out more than $2.2 billion in market capitalization. Investors who purchased Grail securities between May 13, 2025 and February 19, 2026 are now faced with a deadline of August 4, 2026 to file as lead plaintiffs in a securities‑fraud class action alleging that Grail and certain executives made materially false or misleading statements about the trial’s design, results, and future prospects.
The lawsuit, filed as Robbins v. Grail, Inc. (No. 26‑cv‑05428, N.D. Cal.), accuses the company of withholding adverse internal trend‑line data and of overstating the trial’s likelihood of success. Robbins Geller Rudman & Dowd LLP, along with several other law firms, represents the plaintiffs on a contingency basis. Investors who wish to join the class or provide information must contact the plaintiffs’ counsel by the August deadline; failure to do so will preclude participation in the potential recovery.
(Source：scanx.trade)